365
Participants
Start Date
March 18, 2022
Primary Completion Date
April 20, 2024
Study Completion Date
April 20, 2024
L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection
Administered one time via subcutaneous route.
L9LS (VRC-MALMAB0114-00-AB) intravenous injection
Administered one time via intravenous route.
Placebo
Normal saline administered one time via subcutaneous route.
Kalifabougou MRTC Clinic, Kalifabougou
Torodo MRTC Clinic, Torodo
National Institutes of Health (NIH)
NIH
Malaria Research and Training Center, Bamako, Mali
OTHER
University of the Sciences, Techniques and Technologies of Bamako
OTHER
University of Washington
OTHER
Harvard School of Public Health (HSPH)
OTHER
Indiana University School of Medicine
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH